Artesunate is Ineffective in Controlling Valganciclovir-Resistant Cytomegalovirus Infection
نویسندگان
چکیده
منابع مشابه
Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection.
To the Editor—Cytomegalovirus (CMV) disease is a common pathogen and represents a difficult clinical problem in transplant recipients. CMV-naive patients receiving a CMV-positive allograft may experience complications, such as retinitis, gastritis, colitis, and pneumonitis, which may force clinicians to reduce immunosuppressive agents, thereby risking rejection. However oral agents, such as val...
متن کاملValganciclovir: Dosing Strategies for Effective Cytomegalovirus Prevention
Valganciclovir has widely become the agent of choice for the prevention of cytomegalovirus in recipients of organ transplants. Optimal dosing is needed to achieve efficacy and avoid toxicity. For subjects at high risk of cytomegalovirus, it is strongly suggested that full-dose (based on renal function) valganciclovir be used. While low-dose valganciclovir appears to be efficacious in some repor...
متن کاملCytomegalovirus ulcer. Successful treatment with valganciclovir.
A 47-year-old man with multiple-drug–resistant AIDS was admitted to Yale–New Haven Hospital for evaluation of mental status and neuromotor changes and a 6-week history of a painful, nonhealing, enlarging ulcer on the lower extremity that the patient attributed to minor trauma. The patient had received outpatient wound care and several courses of oral antibiotics, but he was taking neither antir...
متن کاملGanciclovir-resistant cytomegalovirus infection in renal transplantation
Cytomegalovirus (CMV) infection is an important cause of morbidity in renal transplant recipients, due to both direct and indirect effects of the virus on the graft and patient [1]. Ganciclovir (GCV) remains the most common first-line therapy, but its low oral bioavailability was identified as a risk factor for the emergence of resistant strains [1], and intravenous (IV) administration is incon...
متن کاملValganciclovir for symptomatic congenital cytomegalovirus disease.
BACKGROUND The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2010
ISSN: 1058-4838,1537-6591
DOI: 10.1093/cid/ciq050